Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

Expanded conditional approval allows drugs that are undergoing their final clinical trial assessment and are supported by ...

A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for ...

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...

The FDA has granted Fast Track designation to eRapa, an encapsulated form of rapamycin, for the treatment of familial adenomatous polyposis.

One such drug is rapamycin, a pill that is typically prescribed to patients ahead of organ transplants "to bring the immune ...

Signaling via mammalian target of rapamycin (mTOR), which is known to control mRNA translation and influence synaptic plasticity, has been studied at the spinal level in neuropathic pain, but its role ...

Researchers from the Organoid group at the Hubrecht Institute have found that specific gut cells, BEST4/CA7+ cells, regulate ...

Biodexa Pharmaceuticals (BDRX) announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway ...

Researchers from the Organoid group at the Hubrecht Institute have found that specific gut cells, BEST4/CA7+ cells, regulate electrolyte and water balance in response to bacterial toxins that cause ...